Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

<i>Background</i>: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (&#8722;) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a firs...

Full description

Bibliographic Details
Main Authors: Valentina Rossi, Paola Berchialla, Diana Giannarelli, Cecilia Nisticò, Gianluigi Ferretti, Simona Gasparro, Michelangelo Russillo, Giovanna Catania, Leonardo Vigna, Rossella Letizia Mancusi, Emilio Bria, Filippo Montemurro, Francesco Cognetti, Alessandra Fabi
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
palbociclib
ribociclib
abemaciclib
fulvestrant
aromatase inhibitors
metastatic breast cancer
Online Access:https://www.mdpi.com/2072-6694/11/11/1661

Internet

https://www.mdpi.com/2072-6694/11/11/1661

Similar Items